Personalized treatment strategy is driving drug development in Asthma, a disease that affects over 235 M people globally. Despite optimization of standard therapies including inhaled corticosteroids and long-acting bronchodilators, ~3-10% of patients have severe asthma.

Click here to learn more : Targeting Endophenotypes In Asthma